GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (NAS:XAIR) » Definitions » Other Financing

XAIR (Beyond Air) Other Financing : $0.30 Mil (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Beyond Air Other Financing?

Beyond Air's Other Financing for the three months ended in Sep. 2024 was $0.09 Mil.

Beyond Air's Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 was $0.30 Mil.


Beyond Air Other Financing Historical Data

The historical data trend for Beyond Air's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beyond Air Other Financing Chart

Beyond Air Annual Data
Trend Jun15 Jun16 Dec17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 6.67 6.25 - 0.22

Beyond Air Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.22 - 0.09

Beyond Air Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beyond Air Other Financing Related Terms

Thank you for viewing the detailed overview of Beyond Air's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Beyond Air Business Description

Traded in Other Exchanges
Address
900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Executives
Robert Carey director HORIZON PHARMA, INC., 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60062
Steven A. Lisi director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Amir Avniel director, officer: President & CEO 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jeff Lynn Myers officer: Chief Medical Officer C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Michael A. Gaul officer: Chief Operating Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
William P Forbes director C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Yoori Lee director C/O AIT THERAPEUTICS, INC., 500 MAMARONECK AVENUE, HARRISON NY 10528
Ron Bentsur director 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Douglas Quinton Larson officer: Chief Financial Officer BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Douglas Beck officer: Chief Financial Officer C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Ari Raved director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
David Grossman director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Haim Aviv officer: Chief Financial Officer 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635